Skip to main
BLLN

Billiontoone Inc (BLLN) Stock Forecast & Price Target

Billiontoone Inc (BLLN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

BillionToOne is a rapidly growing molecular diagnostics company with a diverse portfolio of ultrasensitive tests, including the successful UNITY test for prenatal screening and the upcoming launch of a new MRD test. With a strong focus on reproductive health and a potential for growth in under-penetrated markets and cancer profiling, the company has exceeded expectations and has a buy rating from analysts. Additionally, CEO David Tsao's background in bioengineering and success in raising over $200M in funding showcases strong leadership and potential for future success.

Bears say

BillionToOne is facing significant challenges and risks due to its heavy dependence on government reimbursement and third-party payors for revenue. Their profitability is also at risk as they prioritize cost-effectiveness over growth. The company's prenatal market growth is likely to slow down as it faces competition from larger labs in the NIPT space. Additionally, the success of their pipeline initiatives and future test launches remains uncertain, leaving the company's revenue potential and market acceptance in question.

Billiontoone Inc (BLLN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Billiontoone Inc (BLLN) Forecast

Analysts have given Billiontoone Inc (BLLN) a Buy based on their latest research and market trends.

According to 7 analysts, Billiontoone Inc (BLLN) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Billiontoone Inc (BLLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.